ID   RT109_YEAST             Reviewed;         436 AA.
AC   Q07794; D6VY01;
DT   12-DEC-2006, integrated into UniProtKB/Swiss-Prot.
DT   01-NOV-1996, sequence version 1.
DT   18-JUN-2025, entry version 177.
DE   RecName: Full=Histone acetyltransferase RTT109;
DE            EC=2.3.1.48 {ECO:0000269|PubMed:17272722, ECO:0000269|PubMed:17369253, ECO:0000269|PubMed:17690098, ECO:0000269|PubMed:18707894, ECO:0000269|PubMed:21256037, ECO:0000269|PubMed:29300933, ECO:0000269|PubMed:31194870};
DE   AltName: Full=Regulator of Ty1 transposition protein 109;
GN   Name=RTT109 {ECO:0000303|PubMed:17046836};
GN   Synonyms=KAT11 {ECO:0000303|PubMed:18568037}, KIM2, REM50;
GN   OrderedLocusNames=YLL002W; ORFNames=L1377;
OS   Saccharomyces cerevisiae (strain ATCC 204508 / S288c) (Baker's yeast).
OC   Eukaryota; Fungi; Dikarya; Ascomycota; Saccharomycotina; Saccharomycetes;
OC   Saccharomycetales; Saccharomycetaceae; Saccharomyces.
OX   NCBI_TaxID=559292;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RC   STRAIN=ATCC 204511 / S288c / AB972;
RX   PubMed=8810043;
RX   DOI=10.1002/(sici)1097-0061(19960615)12:7%3c693::aid-yea956%3e3.0.co;2-g;
RA   Miosga T., Zimmermann F.K.;
RT   "Sequence analysis of the CEN12 region of Saccharomyces cerevisiae on a
RT   43.7 kb fragment of chromosome XII including an open reading frame
RT   homologous to the human cystic fibrosis transmembrane conductance regulator
RT   protein CFTR.";
RL   Yeast 12:693-708(1996).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=ATCC 204508 / S288c;
RX   PubMed=9169871; DOI=10.1038/387s087;
RA   Johnston M., Hillier L.W., Riles L., Albermann K., Andre B., Ansorge W.,
RA   Benes V., Brueckner M., Delius H., Dubois E., Duesterhoeft A.,
RA   Entian K.-D., Floeth M., Goffeau A., Hebling U., Heumann K.,
RA   Heuss-Neitzel D., Hilbert H., Hilger F., Kleine K., Koetter P., Louis E.J.,
RA   Messenguy F., Mewes H.-W., Miosga T., Moestl D., Mueller-Auer S.,
RA   Nentwich U., Obermaier B., Piravandi E., Pohl T.M., Portetelle D.,
RA   Purnelle B., Rechmann S., Rieger M., Rinke M., Rose M., Scharfe M.,
RA   Scherens B., Scholler P., Schwager C., Schwarz S., Underwood A.P.,
RA   Urrestarazu L.A., Vandenbol M., Verhasselt P., Vierendeels F., Voet M.,
RA   Volckaert G., Voss H., Wambutt R., Wedler E., Wedler H., Zimmermann F.K.,
RA   Zollner A., Hani J., Hoheisel J.D.;
RT   "The nucleotide sequence of Saccharomyces cerevisiae chromosome XII.";
RL   Nature 387:87-90(1997).
RN   [3]
RP   GENOME REANNOTATION.
RC   STRAIN=ATCC 204508 / S288c;
RX   PubMed=24374639; DOI=10.1534/g3.113.008995;
RA   Engel S.R., Dietrich F.S., Fisk D.G., Binkley G., Balakrishnan R.,
RA   Costanzo M.C., Dwight S.S., Hitz B.C., Karra K., Nash R.S., Weng S.,
RA   Wong E.D., Lloyd P., Skrzypek M.S., Miyasato S.R., Simison M., Cherry J.M.;
RT   "The reference genome sequence of Saccharomyces cerevisiae: Then and now.";
RL   G3 (Bethesda) 4:389-398(2014).
RN   [4]
RP   FUNCTION.
RX   PubMed=11779788; DOI=10.1093/genetics/159.4.1449;
RA   Scholes D.T., Banerjee M., Bowen B., Curcio M.J.;
RT   "Multiple regulators of Ty1 transposition in Saccharomyces cerevisiae have
RT   conserved roles in genome maintenance.";
RL   Genetics 159:1449-1465(2001).
RN   [5]
RP   SUBCELLULAR LOCATION [LARGE SCALE ANALYSIS].
RX   PubMed=14562095; DOI=10.1038/nature02026;
RA   Huh W.-K., Falvo J.V., Gerke L.C., Carroll A.S., Howson R.W.,
RA   Weissman J.S., O'Shea E.K.;
RT   "Global analysis of protein localization in budding yeast.";
RL   Nature 425:686-691(2003).
RN   [6]
RP   LEVEL OF PROTEIN EXPRESSION [LARGE SCALE ANALYSIS].
RX   PubMed=14562106; DOI=10.1038/nature02046;
RA   Ghaemmaghami S., Huh W.-K., Bower K., Howson R.W., Belle A., Dephoure N.,
RA   O'Shea E.K., Weissman J.S.;
RT   "Global analysis of protein expression in yeast.";
RL   Nature 425:737-741(2003).
RN   [7]
RP   INDUCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=15282802; DOI=10.1002/yea.1133;
RA   Sundin B.A., Chiu C.-H., Riffle M., Davis T.N., Muller E.G.D.;
RT   "Localization of proteins that are coordinately expressed with Cln2 during
RT   the cell cycle.";
RL   Yeast 21:793-800(2004).
RN   [8]
RP   FUNCTION.
RX   PubMed=17046836; DOI=10.1074/jbc.c600265200;
RA   Schneider J., Bajwa P., Johnson F.C., Bhaumik S.R., Shilatifard A.;
RT   "Rtt109 is required for proper H3K56 acetylation: a chromatin mark
RT   associated with the elongating RNA polymerase II.";
RL   J. Biol. Chem. 281:37270-37274(2006).
RN   [9]
RP   FUNCTION, CATALYTIC ACTIVITY, AND INTERACTION WITH VPS75.
RX   PubMed=17369253; DOI=10.1074/jbc.m700611200;
RA   Han J., Zhou H., Li Z., Xu R.-M., Zhang Z.;
RT   "The Rtt109-Vps75 histone acetyltransferase complex acetylates non-
RT   nucleosomal histone H3.";
RL   J. Biol. Chem. 282:14158-14164(2007).
RN   [10]
RP   FUNCTION, CATALYTIC ACTIVITY, AND INTERACTION WITH ASF1 AND VPS75.
RX   PubMed=17690098; DOI=10.1074/jbc.m702496200;
RA   Han J., Zhou H., Li Z., Xu R.-M., Zhang Z.;
RT   "Acetylation of lysine 56 of histone H3 catalyzed by RTT109 and regulated
RT   by ASF1 is required for replisome integrity.";
RL   J. Biol. Chem. 282:28587-28596(2007).
RN   [11]
RP   FUNCTION, IDENTIFICATION IN A COMPLEX WITH VPS75, AND INTERACTION WITH ASF1
RP   AND VPS75.
RX   PubMed=17320445; DOI=10.1016/j.molcel.2007.02.006;
RA   Tsubota T., Berndsen C.E., Erkmann J.A., Smith C.L., Yang L., Freitas M.A.,
RA   Denu J.M., Kaufman P.D.;
RT   "Histone H3-K56 acetylation is catalyzed by histone chaperone-dependent
RT   complexes.";
RL   Mol. Cell 25:703-712(2007).
RN   [12]
RP   FUNCTION, AND CATALYTIC ACTIVITY.
RX   PubMed=17272722; DOI=10.1126/science.1135862;
RA   Driscoll R., Hudson A., Jackson S.P.;
RT   "Yeast Rtt109 promotes genome stability by acetylating histone H3 on lysine
RT   56.";
RL   Science 315:649-652(2007).
RN   [13]
RP   FUNCTION, MUTAGENESIS OF ASP-89 AND 287-ASP-ASP-288, AND INTERACTION WITH
RP   VPS75.
RX   PubMed=17272723; DOI=10.1126/science.1133234;
RA   Han J., Zhou H., Horazdovsky B., Zhang K., Xu R.-M., Zhang Z.;
RT   "Rtt109 acetylates histone H3 lysine 56 and functions in DNA replication.";
RL   Science 315:653-655(2007).
RN   [14]
RP   FUNCTION, CATALYTIC ACTIVITY, BIOPHYSICOCHEMICAL PROPERTIES, INTERACTION
RP   WITH HISTONE H3/H4 HETERODIMERS, AND DISRUPTION PHENOTYPE.
RX   PubMed=19172748; DOI=10.1038/nsmb.1459;
RA   Berndsen C.E., Tsubota T., Lindner S.E., Lee S., Holton J.M., Kaufman P.D.,
RA   Keck J.L., Denu J.M.;
RT   "Molecular functions of the histone acetyltransferase chaperone complex
RT   Rtt109-Vps75.";
RL   Nat. Struct. Mol. Biol. 15:948-956(2008).
RN   [15]
RP   FUNCTION.
RX   PubMed=18577595; DOI=10.1073/pnas.0800057105;
RA   Williams S.K., Truong D., Tyler J.K.;
RT   "Acetylation in the globular core of histone H3 on lysine-56 promotes
RT   chromatin disassembly during transcriptional activation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:9000-9005(2008).
RN   [16]
RP   FUNCTION, AND INTERACTION WITH VPS75.
RX   PubMed=18723682; DOI=10.1073/pnas.0802393105;
RA   Tang Y., Meeth K., Jiang E., Luo C., Marmorstein R.;
RT   "Structure of Vps75 and implications for histone chaperone function.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:12206-12211(2008).
RN   [17]
RP   FUNCTION, AND DISRUPTION PHENOTYPE.
RX   PubMed=19683497; DOI=10.1016/j.molcel.2009.06.023;
RA   Fillingham J., Kainth P., Lambert J.P., van Bakel H., Tsui K.,
RA   Pena-Castillo L., Nislow C., Figeys D., Hughes T.R., Greenblatt J.,
RA   Andrews B.J.;
RT   "Two-color cell array screen reveals interdependent roles for histone
RT   chaperones and a chromatin boundary regulator in histone gene repression.";
RL   Mol. Cell 35:340-351(2009).
RN   [18]
RP   FUNCTION, BIOPHYSIOCHEMICAL PROPERTIES, IDENTIFICATION IN A COMPLEX WITH
RP   VPS75, INTERACTION WITH VPS75, AND MUTAGENESIS OF ASP-287 AND ASP-288.
RX   PubMed=20560668; DOI=10.1021/bi100381y;
RA   Albaugh B.N., Kolonko E.M., Denu J.M.;
RT   "Kinetic mechanism of the Rtt109-Vps75 histone acetyltransferase-chaperone
RT   complex.";
RL   Biochemistry 49:6375-6385(2010).
RN   [19]
RP   FUNCTION, AND CATALYTIC ACTIVITY.
RX   PubMed=31194870; DOI=10.1093/nar/gkz508;
RA   Cote J.M., Kuo Y.M., Henry R.A., Scherman H., Krzizike D.D., Andrews A.J.;
RT   "Two factor authentication: Asf1 mediates crosstalk between H3 K14 and K56
RT   acetylation.";
RL   Nucleic Acids Res. 47:7380-7391(2019).
RN   [20] {ECO:0007744|PDB:3QM0}
RP   X-RAY CRYSTALLOGRAPHY (3.10 ANGSTROMS) OF 1-129 AND 180-436 IN COMPLEX WITH
RP   ACETYL-COA, FUNCTION, CATALYTIC ACTIVITY, BIOPHYSICOCHEMICAL PROPERTIES,
RP   DISRUPTION PHENOTYPE, ACETYLATION AT LYS-290, AND MUTAGENESIS OF ASP-89;
RP   TYR-199; TRP-222; ASP-287 AND LYS-290.
RX   PubMed=18568037; DOI=10.1038/nsmb.1448;
RA   Tang Y., Holbert M.A., Wurtele H., Meeth K., Rocha W., Gharib M., Jiang E.,
RA   Thibault P., Verreault A., Cole P.A., Marmorstein R.;
RT   "Fungal Rtt109 histone acetyltransferase is an unexpected structural
RT   homolog of metazoan p300/CBP.";
RL   Nat. Struct. Mol. Biol. 15:738-745(2008).
RN   [21] {ECO:0007744|PDB:3CZ7}
RP   X-RAY CRYSTALLOGRAPHY (2.00 ANGSTROMS) OF 1-127 AND 171-403 IN COMPLEX WITH
RP   ACETYL-COA, FUNCTION, IDENTIFICATION IN A COMPLEX WITH VPS75, INTERACTION
RP   WITH VPS75, DISRUPTION PHENOTYPE, ACETYLATION AT LYS-290, AND MUTAGENESIS
RP   OF GLU-66; PHE-84; PHE-285; ASP-287; ASP-288; LYS-290 AND TRP-312.
RX   PubMed=18719104; DOI=10.1073/pnas.0805813105;
RA   Stavropoulos P., Nagy V., Blobel G., Hoelz A.;
RT   "Molecular basis for the autoregulation of the protein acetyl transferase
RT   Rtt109.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:12236-12241(2008).
RN   [22] {ECO:0007744|PDB:2RIM, ECO:0007744|PDB:2ZFN}
RP   X-RAY CRYSTALLOGRAPHY (1.9 ANGSTROMS) IN COMPLEX WITH ACETYL-COA, FUNCTION,
RP   CATALYTIC ACTIVITY, ACTIVE SITE, ACETYLATION AT LYS-290, AND MUTAGENESIS OF
RP   ASP-89; ARG-194; HIS-211; TRP-221; ASP-288 AND LYS-290.
RX   PubMed=18707894; DOI=10.1016/j.str.2008.07.006;
RA   Lin C., Yuan Y.A.;
RT   "Structural insights into histone H3 lysine 56 acetylation by Rtt109.";
RL   Structure 16:1503-1510(2008).
RN   [23] {ECO:0007744|PDB:3Q66, ECO:0007744|PDB:3Q68}
RP   X-RAY CRYSTALLOGRAPHY (2.71 ANGSTROMS) OF 1-426 IN COMPLEX WITH VPS75, AND
RP   INTERACTION WITH VPS75 AND HISTONE H3/H4 HETERODIMERS.
RX   PubMed=21454705; DOI=10.1074/jbc.c111.220715;
RA   Su D., Hu Q., Zhou H., Thompson J.R., Xu R.M., Zhang Z., Mer G.;
RT   "Structure and histone binding properties of the Vps75-Rtt109 chaperone-
RT   lysine acetyltransferase complex.";
RL   J. Biol. Chem. 286:15625-15629(2011).
RN   [24] {ECO:0007744|PDB:3Q33, ECO:0007744|PDB:3Q35}
RP   X-RAY CRYSTALLOGRAPHY (2.80 ANGSTROMS) OF 1-129; 134-165 AND 172-404 IN
RP   COMPLEX WITH ACETYL-COA AND VPS75, FUNCTION, CATALYTIC ACTIVITY,
RP   INTERACTION WITH VPS75, DISRUPTION PHENOTYPE, AND MUTAGENESIS OF LEU-148;
RP   150-ILE-LEU-151; ARG-292; 355-ARG-LYS-356; 368-GLU--ASP-371; GLU-368;
RP   GLU-374; 378-GLU--ASN-382 AND GLU-378.
RX   PubMed=21256037; DOI=10.1016/j.str.2010.12.012;
RA   Tang Y., Holbert M.A., Delgoshaie N., Wurtele H., Guillemette B., Meeth K.,
RA   Yuan H., Drogaris P., Lee E.H., Durette C., Thibault P., Verreault A.,
RA   Cole P.A., Marmorstein R.;
RT   "Structure of the Rtt109-AcCoA/Vps75 complex and implications for
RT   chaperone-mediated histone acetylation.";
RL   Structure 19:221-231(2011).
RN   [25] {ECO:0007744|PDB:6F0Y}
RP   STRUCTURE BY NMR OF 419-433, FUNCTION, CATALYTIC ACTIVITY, AND INTERACTION
RP   WITH ASF1.
RX   PubMed=29300933; DOI=10.1093/nar/gkx1283;
RA   Lercher L., Danilenko N., Kirkpatrick J., Carlomagno T.;
RT   "Structural characterization of the Asf1-Rtt109 interaction and its role in
RT   histone acetylation.";
RL   Nucleic Acids Res. 46:2279-2289(2018).
RN   [26] {ECO:0007744|PDB:6O22}
RP   STRUCTURE BY NMR IN COMPLEX WITH VPS75 AND ASF1, INTERACTION WITH ASF1 AND
RP   VPS75, AND MUTAGENESIS OF 425-LYS--THR-436.
RX   PubMed=31387991; DOI=10.1038/s41467-019-11410-7;
RA   Danilenko N., Lercher L., Kirkpatrick J., Gabel F., Codutti L.,
RA   Carlomagno T.;
RT   "Histone chaperone exploits intrinsic disorder to switch acetylation
RT   specificity.";
RL   Nat. Commun. 10:3435-3435(2019).
CC   -!- FUNCTION: Histone chaperone-dependent acetylase that modifies 'Lys-9',
CC       'Lys-14', 'Lys-23', 'Lys-27', and 'Lys-56' on histone H3 (H3K9Ac,
CC       H3K14Ac and H3K23Ac, H3K27Ac, and H3K56Ac) to promote nucleosome
CC       assembly, genomic stability, DNA repair and transcriptional regulation
CC       during mitotic S-phase (PubMed:17046836, PubMed:17272723,
CC       PubMed:17320445, PubMed:17369253, PubMed:18723682, PubMed:19172748,
CC       PubMed:19683497, PubMed:20560668, PubMed:21256037, PubMed:29300933,
CC       PubMed:31194870). Its residue selectivity is influenced by the
CC       acetylation status of histone H3, and also the presence of histone
CC       chaperone ASF1 that shifts selectivity to 'Lys-56' when H3K14Ac is
CC       already present (PubMed:31194870). H3K56 acetylation weakens the
CC       interaction between the histone core and the surrounding DNA in the
CC       nucleosomal particle and drives chromatin disassembly
CC       (PubMed:18577595). Autoacetylates (PubMed:18568037, PubMed:18707894,
CC       PubMed:18719104). Independently of acetyltransferase activity,
CC       stimulates histone deposition by VPS75 (PubMed:19172748). Involved in
CC       regulation of Ty1 transposition (PubMed:11779788).
CC       {ECO:0000269|PubMed:11779788, ECO:0000269|PubMed:17046836,
CC       ECO:0000269|PubMed:17272723, ECO:0000269|PubMed:17320445,
CC       ECO:0000269|PubMed:17369253, ECO:0000269|PubMed:18568037,
CC       ECO:0000269|PubMed:18577595, ECO:0000269|PubMed:18707894,
CC       ECO:0000269|PubMed:18719104, ECO:0000269|PubMed:18723682,
CC       ECO:0000269|PubMed:19172748, ECO:0000269|PubMed:19683497,
CC       ECO:0000269|PubMed:20560668, ECO:0000269|PubMed:21256037,
CC       ECO:0000269|PubMed:29300933, ECO:0000269|PubMed:31194870}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=L-lysyl-[histone] + acetyl-CoA = N(6)-acetyl-L-lysyl-[histone]
CC         + CoA + H(+); Xref=Rhea:RHEA:21992, Rhea:RHEA-COMP:9845, Rhea:RHEA-
CC         COMP:11338, ChEBI:CHEBI:15378, ChEBI:CHEBI:29969, ChEBI:CHEBI:57287,
CC         ChEBI:CHEBI:57288, ChEBI:CHEBI:61930; EC=2.3.1.48;
CC         Evidence={ECO:0000269|PubMed:17272722, ECO:0000269|PubMed:17369253,
CC         ECO:0000269|PubMed:17690098, ECO:0000269|PubMed:18568037,
CC         ECO:0000269|PubMed:18707894, ECO:0000269|PubMed:19172748,
CC         ECO:0000269|PubMed:21256037, ECO:0000269|PubMed:29300933,
CC         ECO:0000269|PubMed:31194870};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:21993;
CC         Evidence={ECO:0000269|PubMed:17272722, ECO:0000269|PubMed:17369253,
CC         ECO:0000269|PubMed:17690098, ECO:0000269|PubMed:18568037,
CC         ECO:0000269|PubMed:18707894, ECO:0000269|PubMed:19172748,
CC         ECO:0000269|PubMed:21256037, ECO:0000269|PubMed:29300933,
CC         ECO:0000269|PubMed:31194870};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=L-lysyl-[protein] + acetyl-CoA = N(6)-acetyl-L-lysyl-[protein]
CC         + CoA + H(+); Xref=Rhea:RHEA:45948, Rhea:RHEA-COMP:9752, Rhea:RHEA-
CC         COMP:10731, ChEBI:CHEBI:15378, ChEBI:CHEBI:29969, ChEBI:CHEBI:57287,
CC         ChEBI:CHEBI:57288, ChEBI:CHEBI:61930; EC=2.3.1.48;
CC         Evidence={ECO:0000269|PubMed:18568037, ECO:0000269|PubMed:18707894,
CC         ECO:0000269|PubMed:18719104};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:45949;
CC         Evidence={ECO:0000269|PubMed:18568037, ECO:0000269|PubMed:18707894,
CC         ECO:0000269|PubMed:18719104};
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=0.3 uM for acetyl-CoA (at pH 7.5, 25 degrees Celsius in the
CC         presence of VPS75 chaperone) {ECO:0000269|PubMed:20560668};
CC         KM=8 uM for acetyl-CoA (at pH 8, 30 degrees Celsius in the presence
CC         of VPS75 chaperone) {ECO:0000269|PubMed:18568037};
CC         KM=1 uM for acetyl-CoA (at pH 7.0, 25 degrees Celsius in the presence
CC         of VPS75 chaperone) {ECO:0000269|PubMed:19172748};
CC         KM=0.3 uM for acetyl-CoA (at pH 7.0, 25 degrees Celsius)
CC         {ECO:0000269|PubMed:19172748};
CC         KM=7 uM for histone H3 (at pH 7.5, 25 degrees Celsius in the presence
CC         of VPS75 chaperone) {ECO:0000269|PubMed:20560668};
CC         KM=8.5 uM for histone H3 (at pH 8, 30 degrees Celsius in the presence
CC         of VPS75 chaperone) {ECO:0000269|PubMed:18568037};
CC         KM=8.1 uM for histone H3 (at pH 7.0, 25 degrees Celsius)
CC         {ECO:0000269|PubMed:19172748};
CC         KM=1.4 uM for histone H3/H4 (at pH 7.0, 25 degrees Celsius in the
CC         presence of VPS75 chaperone) {ECO:0000269|PubMed:19172748};
CC         KM=2.9 uM for histone H3/H4 (at pH 7.0, 25 degrees Celsius)
CC         {ECO:0000269|PubMed:19172748};
CC         Note=kcat is 0.11 sec(-1) with acetyl-CoA as substrate (at pH 7.5, 25
CC         degrees Celsius in the presence of VPS75 chaperone)
CC         (PubMed:20560668). kcat is 0.19 sec(-1) with acetyl-CoA as substrate
CC         (at pH 7.0, 25 degrees Celsius in the presence of VPS75 chaperone)
CC         (PubMed:19172748). kcat is 0.0017 sec(-1) with acetyl-CoA as
CC         substrate (at pH 7.0, 25 degrees Celsius) (PubMed:19172748). kcat is
CC         0.62 sec(-1) with histone H3 as substrate (at pH 7.5, 25 degrees
CC         Celsius in the presence of VPS75 chaperone) (PubMed:20560668). kcat
CC         is 22.5 min(-1) with histone H3 (at pH 8, 30 degrees Celsius in the
CC         presence of VPS75 chaperone) (PubMed:18568037). kcat is 0.0033
CC         sec(-1) with acetyl-CoA as substrate (at pH 7.0, 25 degrees Celsius)
CC         (PubMed:19172748). kcat is 0.11 sec(-1) with histone H3/H4 as
CC         substrate (at pH 7.0, 25 degrees Celsius in the presence of VPS75
CC         chaperone) (PubMed:19172748). kcat is 0.0033 sec(-1) with histone
CC         H3/H4 as substrate (at pH 7.0, 25 degrees Celsius) (PubMed:19172748).
CC         {ECO:0000269|PubMed:18568037, ECO:0000269|PubMed:19172748,
CC         ECO:0000269|PubMed:20560668};
CC       pH dependence:
CC         Optimum pH is >8.5. {ECO:0000269|PubMed:20560668};
CC   -!- SUBUNIT: Forms a complex composed of two RTT109 subunits and one VPS75
CC       homodimer; each RTT109 subunit interacts predominantly with VPS75
CC       instead of interacting with the other RTT109 subunit (PubMed:17320445,
CC       PubMed:18719104, PubMed:20560668, PubMed:21256037, PubMed:31387991).
CC       Interacts with VPS75; the interaction is direct (PubMed:17272723,
CC       PubMed:17320445, PubMed:17369253, PubMed:17690098, PubMed:18719104,
CC       PubMed:18723682, PubMed:20560668, PubMed:21256037, PubMed:31387991).
CC       Interacts (via C-terminus) with ASF1; the interaction is direct
CC       (PubMed:17320445, PubMed:17690098, PubMed:29300933, PubMed:31387991).
CC       Interacts with histone H3/H4 heterodimers via histone H3
CC       (PubMed:19172748, PubMed:21454705). {ECO:0000269|PubMed:17272723,
CC       ECO:0000269|PubMed:17320445, ECO:0000269|PubMed:17369253,
CC       ECO:0000269|PubMed:17690098, ECO:0000269|PubMed:18719104,
CC       ECO:0000269|PubMed:18723682, ECO:0000269|PubMed:19172748,
CC       ECO:0000269|PubMed:20560668, ECO:0000269|PubMed:21256037,
CC       ECO:0000269|PubMed:21454705, ECO:0000269|PubMed:29300933,
CC       ECO:0000269|PubMed:31387991}.
CC   -!- INTERACTION:
CC       Q07794; P25293: NAP1; NbExp=2; IntAct=EBI-2887026, EBI-11850;
CC       Q07794; P53853: VPS75; NbExp=21; IntAct=EBI-2887026, EBI-29225;
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:14562095,
CC       ECO:0000269|PubMed:15282802}.
CC   -!- INDUCTION: Expression peaks in cell cycle G1.
CC       {ECO:0000269|PubMed:15282802}.
CC   -!- DISRUPTION PHENOTYPE: Abolishes acetylation of histone H3 'Lys-56';
CC       simultaneous disruption of GCN5 also abolishes acetylation of histone
CC       H3 'Lys-9' and 'Lys-27' (PubMed:21256037). Decreases acetylation of
CC       histone H3 'Lys-9' and 'Lys-23' (PubMed:19172748). Decreases HTA1 RNA
CC       level; simultaneous disruption of HIR1 or RTT106 alleviates the effect
CC       (PubMed:19683497). Increases sensitivity to methyl methane sulfonate,
CC       hydroxyurea, and camptothecin (genotoxic stress) (PubMed:18568037,
CC       PubMed:18719104). {ECO:0000269|PubMed:18568037,
CC       ECO:0000269|PubMed:18719104, ECO:0000269|PubMed:19172748,
CC       ECO:0000269|PubMed:19683497, ECO:0000269|PubMed:21256037}.
CC   -!- MISCELLANEOUS: Present with 1140 molecules/cell in log phase SD medium.
CC       {ECO:0000269|PubMed:14562106}.
CC   -!- SIMILARITY: Belongs to the RTT109 family. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; X91488; CAA62768.1; -; Genomic_DNA.
DR   EMBL; Z73107; CAA97445.1; -; Genomic_DNA.
DR   EMBL; BK006945; DAA09317.1; -; Genomic_DNA.
DR   PIR; S64744; S64744.
DR   RefSeq; NP_013099.1; NM_001181822.1.
DR   PDB; 2RIM; X-ray; 2.20 A; A=1-436.
DR   PDB; 2ZFN; X-ray; 1.90 A; A=1-436.
DR   PDB; 3CZ7; X-ray; 2.00 A; A=1-127, A=171-403.
DR   PDB; 3Q33; X-ray; 2.80 A; A=1-436.
DR   PDB; 3Q35; X-ray; 3.30 A; A=1-436.
DR   PDB; 3Q66; X-ray; 2.70 A; C=1-436.
DR   PDB; 3Q68; X-ray; 2.70 A; C=1-436.
DR   PDB; 3QM0; X-ray; 3.10 A; A=1-436.
DR   PDB; 6F0Y; NMR; -; B=419-433.
DR   PDB; 6O22; Other; -; C=1-436.
DR   PDBsum; 2RIM; -.
DR   PDBsum; 2ZFN; -.
DR   PDBsum; 3CZ7; -.
DR   PDBsum; 3Q33; -.
DR   PDBsum; 3Q35; -.
DR   PDBsum; 3Q66; -.
DR   PDBsum; 3Q68; -.
DR   PDBsum; 3QM0; -.
DR   PDBsum; 6F0Y; -.
DR   PDBsum; 6O22; -.
DR   AlphaFoldDB; Q07794; -.
DR   SASBDB; Q07794; -.
DR   SMR; Q07794; -.
DR   BioGRID; 31249; 598.
DR   ComplexPortal; CPX-1333; RTT109-VPS75 histone acetyltransferase complex.
DR   DIP; DIP-8842N; -.
DR   FunCoup; Q07794; 57.
DR   IntAct; Q07794; 6.
DR   MINT; Q07794; -.
DR   STRING; 4932.YLL002W; -.
DR   ChEMBL; CHEMBL3414417; -.
DR   GlyGen; Q07794; 2 sites.
DR   iPTMnet; Q07794; -.
DR   PaxDb; 4932-YLL002W; -.
DR   PeptideAtlas; Q07794; -.
DR   EnsemblFungi; YLL002W_mRNA; YLL002W; YLL002W.
DR   GeneID; 850658; -.
DR   KEGG; sce:YLL002W; -.
DR   AGR; SGD:S000003925; -.
DR   SGD; S000003925; RTT109.
DR   VEuPathDB; FungiDB:YLL002W; -.
DR   eggNOG; KOG4534; Eukaryota.
DR   GeneTree; ENSGT00940000176814; -.
DR   HOGENOM; CLU_050421_0_0_1; -.
DR   InParanoid; Q07794; -.
DR   OMA; FLEHLIV; -.
DR   OrthoDB; 3361892at2759; -.
DR   BioCyc; YEAST:G3O-32107-MONOMER; -.
DR   BRENDA; 2.3.1.48; 984.
DR   BioGRID-ORCS; 850658; 0 hits in 10 CRISPR screens.
DR   EvolutionaryTrace; Q07794; -.
DR   PRO; PR:Q07794; -.
DR   Proteomes; UP000002311; Chromosome XII.
DR   RNAct; Q07794; protein.
DR   GO; GO:0000785; C:chromatin; IDA:ComplexPortal.
DR   GO; GO:0070775; C:H3 histone acetyltransferase complex; IDA:UniProtKB.
DR   GO; GO:0005634; C:nucleus; IDA:SGD.
DR   GO; GO:0010484; F:histone H3 acetyltransferase activity; IDA:SGD.
DR   GO; GO:0036408; F:histone H3K14 acetyltransferase activity; IDA:UniProtKB.
DR   GO; GO:0043994; F:histone H3K23 acetyltransferase activity; IDA:UniProtKB.
DR   GO; GO:0044017; F:histone H3K27 acetyltransferase activity; IDA:UniProtKB.
DR   GO; GO:0032931; F:histone H3K56 acetyltransferase activity; IDA:UniProtKB.
DR   GO; GO:0043992; F:histone H3K9 acetyltransferase activity; IDA:UniProtKB.
DR   GO; GO:0061733; F:protein-lysine-acetyltransferase activity; IMP:UniProtKB.
DR   GO; GO:0033554; P:cellular response to stress; IMP:SGD.
DR   GO; GO:0006974; P:DNA damage response; IBA:GO_Central.
DR   GO; GO:0043007; P:maintenance of rDNA; IGI:SGD.
DR   GO; GO:0006334; P:nucleosome assembly; IDA:UniProtKB.
DR   GO; GO:0036211; P:protein modification process; IDA:UniProtKB.
DR   GO; GO:2001032; P:regulation of double-strand break repair via nonhomologous end joining; IMP:SGD.
DR   GO; GO:0010468; P:regulation of gene expression; IMP:SGD.
DR   GO; GO:0006357; P:regulation of transcription by RNA polymerase II; IMP:SGD.
DR   GO; GO:1990414; P:replication-born double-strand break repair via sister chromatid exchange; IMP:SGD.
DR   GO; GO:0010526; P:transposable element silencing; IMP:SGD.
DR   IDEAL; IID50225; -.
DR   InterPro; IPR051236; HAT_RTT109-like.
DR   InterPro; IPR013178; Histone_AcTrfase_Rtt109/CBP.
DR   InterPro; IPR016849; Rtt109.
DR   PANTHER; PTHR31571; ALTERED INHERITANCE OF MITOCHONDRIA PROTEIN 6; 1.
DR   PANTHER; PTHR31571:SF2; HISTONE ACETYLTRANSFERASE RTT109; 1.
DR   Pfam; PF08214; HAT_KAT11; 1.
DR   PIRSF; PIRSF027124; Histone_acetylase_Rtt109; 1.
DR   SMART; SM01250; KAT11; 1.
DR   PROSITE; PS51728; RTT109_HAT; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; DNA damage; Nucleus; Reference proteome;
KW   Transcription; Transcription regulation; Transferase.
FT   CHAIN           1..436
FT                   /note="Histone acetyltransferase RTT109"
FT                   /id="PRO_0000268738"
FT   DOMAIN          2..404
FT                   /note="Rtt109-type HAT"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01064"
FT   REGION          128..170
FT                   /note="Interaction with VPS75"
FT                   /evidence="ECO:0000269|PubMed:18719104,
FT                   ECO:0000269|PubMed:21256037, ECO:0000269|PubMed:21454705"
FT   REGION          419..433
FT                   /note="Interaction with ASF1"
FT                   /evidence="ECO:0000269|PubMed:31387991"
FT   ACT_SITE        288
FT                   /note="Proton donor/acceptor"
FT                   /evidence="ECO:0000269|PubMed:18707894"
FT   BINDING         88..90
FT                   /ligand="acetyl-CoA"
FT                   /ligand_id="ChEBI:CHEBI:57288"
FT                   /evidence="ECO:0000269|PubMed:18568037,
FT                   ECO:0000269|PubMed:18707894, ECO:0000269|PubMed:18719104,
FT                   ECO:0000269|PubMed:21256037, ECO:0007744|PDB:2ZFN,
FT                   ECO:0007744|PDB:3CZ7, ECO:0007744|PDB:3Q33,
FT                   ECO:0007744|PDB:3Q35, ECO:0007744|PDB:3QM0"
FT   BINDING         97..101
FT                   /ligand="acetyl-CoA"
FT                   /ligand_id="ChEBI:CHEBI:57288"
FT                   /evidence="ECO:0000269|PubMed:18568037,
FT                   ECO:0000269|PubMed:18707894, ECO:0000269|PubMed:18719104,
FT                   ECO:0000269|PubMed:21256037, ECO:0007744|PDB:2ZFN,
FT                   ECO:0007744|PDB:3CZ7, ECO:0007744|PDB:3Q33,
FT                   ECO:0007744|PDB:3Q35, ECO:0007744|PDB:3QM0"
FT   BINDING         192
FT                   /ligand="acetyl-CoA"
FT                   /ligand_id="ChEBI:CHEBI:57288"
FT                   /evidence="ECO:0000269|PubMed:18568037,
FT                   ECO:0007744|PDB:3QM0"
FT   BINDING         196
FT                   /ligand="acetyl-CoA"
FT                   /ligand_id="ChEBI:CHEBI:57288"
FT                   /evidence="ECO:0000269|PubMed:18568037,
FT                   ECO:0000269|PubMed:21256037, ECO:0007744|PDB:3Q33,
FT                   ECO:0007744|PDB:3Q35, ECO:0007744|PDB:3QM0"
FT   BINDING         211..213
FT                   /ligand="acetyl-CoA"
FT                   /ligand_id="ChEBI:CHEBI:57288"
FT                   /evidence="ECO:0000269|PubMed:18568037,
FT                   ECO:0000269|PubMed:18707894, ECO:0000269|PubMed:18719104,
FT                   ECO:0000269|PubMed:21256037, ECO:0007744|PDB:2ZFN,
FT                   ECO:0007744|PDB:3CZ7, ECO:0007744|PDB:3Q33,
FT                   ECO:0007744|PDB:3Q35, ECO:0007744|PDB:3QM0"
FT   BINDING         221
FT                   /ligand="acetyl-CoA"
FT                   /ligand_id="ChEBI:CHEBI:57288"
FT                   /evidence="ECO:0000269|PubMed:18707894,
FT                   ECO:0000269|PubMed:18719104, ECO:0000269|PubMed:21256037,
FT                   ECO:0007744|PDB:2ZFN, ECO:0007744|PDB:3CZ7,
FT                   ECO:0007744|PDB:3Q33, ECO:0007744|PDB:3Q35"
FT   MOD_RES         290
FT                   /note="N6-acetyllysine; by autocatalysis"
FT                   /evidence="ECO:0000269|PubMed:18568037,
FT                   ECO:0000269|PubMed:18707894, ECO:0000269|PubMed:18719104"
FT   MUTAGEN         66
FT                   /note="E->A: Mildly increases sensitivity to methyl methane
FT                   sulfonate, camptothecin and hydroxyurea (genotoxic
FT                   stress)."
FT                   /evidence="ECO:0000269|PubMed:18719104"
FT   MUTAGEN         84
FT                   /note="F->A: Increases sensitivity to methyl methane
FT                   sulfonate, camptothecin and hydroxyurea (genotoxic
FT                   stress)."
FT                   /evidence="ECO:0000269|PubMed:18719104"
FT   MUTAGEN         89
FT                   /note="D->A: Abolishes histone acetylase activity."
FT                   /evidence="ECO:0000269|PubMed:17272723,
FT                   ECO:0000269|PubMed:18707894"
FT   MUTAGEN         89
FT                   /note="D->N: Decreases histone acetylase activity.
FT                   Decreases expression (at protein level). Increases
FT                   sensitivity to methyl methane sulfonate and hydroxyurea
FT                   (genotoxic stress)."
FT                   /evidence="ECO:0000269|PubMed:18568037"
FT   MUTAGEN         148
FT                   /note="L->D: Decreases binding and activity stimulation by
FT                   VPS75. Decreases acetylation of histone H3 'Lys-9' and
FT                   'Lys-27'."
FT                   /evidence="ECO:0000269|PubMed:21256037"
FT   MUTAGEN         150..151
FT                   /note="IL->DD: Decreases binding and activity stimulation
FT                   by VPS75."
FT                   /evidence="ECO:0000269|PubMed:21256037"
FT   MUTAGEN         194
FT                   /note="R->A,E: Decreases histone acetylase activity."
FT                   /evidence="ECO:0000269|PubMed:18707894,
FT                   ECO:0000269|PubMed:21256037"
FT   MUTAGEN         199
FT                   /note="Y->S: Decreases histone acetylase activity.
FT                   Increases sensitivity to methyl methane sulfonate and
FT                   hydroxyurea (genotoxic stress)."
FT                   /evidence="ECO:0000269|PubMed:18568037"
FT   MUTAGEN         211
FT                   /note="H->A: Decreases histone acetylase activity; when
FT                   associated with A-222."
FT                   /evidence="ECO:0000269|PubMed:18707894"
FT   MUTAGEN         221
FT                   /note="W->A: Decreases histone acetylase activity; when
FT                   associated with A-211."
FT                   /evidence="ECO:0000269|PubMed:18707894"
FT   MUTAGEN         222
FT                   /note="W->F: Decreases histone acetylase activity.
FT                   Increases sensitivity to methyl methane sulfonate and
FT                   hydroxyurea (genotoxic stress)."
FT                   /evidence="ECO:0000269|PubMed:18568037"
FT   MUTAGEN         285
FT                   /note="F->A: Increases sensitivity to methyl methane
FT                   sulfonate, camptothecin and hydroxyurea (genotoxic
FT                   stress)."
FT                   /evidence="ECO:0000269|PubMed:18719104"
FT   MUTAGEN         287..288
FT                   /note="DD->AA,NN: Decreases histone acetylase activity."
FT                   /evidence="ECO:0000269|PubMed:17272723,
FT                   ECO:0000269|PubMed:20560668"
FT   MUTAGEN         287
FT                   /note="D->A,N: Decreases histone acetylase activity."
FT                   /evidence="ECO:0000269|PubMed:18568037,
FT                   ECO:0000269|PubMed:20560668"
FT   MUTAGEN         287
FT                   /note="D->A: Increases sensitivity to methyl methane
FT                   sulfonate, camptothecin and hydroxyurea (genotoxic
FT                   stress)."
FT                   /evidence="ECO:0000269|PubMed:18719104"
FT   MUTAGEN         288
FT                   /note="D->A: Abolishes histone acetylase activity.
FT                   Increases sensitivity to methyl methane sulfonate,
FT                   camptothecin and hydroxyurea (genotoxic stress)."
FT                   /evidence="ECO:0000269|PubMed:18707894,
FT                   ECO:0000269|PubMed:18719104"
FT   MUTAGEN         288
FT                   /note="D->N: Decreases histone acetylase activity."
FT                   /evidence="ECO:0000269|PubMed:20560668"
FT   MUTAGEN         290
FT                   /note="K->A: Abolishes histone acetylase activity.
FT                   Increases sensitivity to methyl methane sulfonate,
FT                   camptothecin and hydroxyurea (genotoxic stress)."
FT                   /evidence="ECO:0000269|PubMed:18707894,
FT                   ECO:0000269|PubMed:18719104"
FT   MUTAGEN         290
FT                   /note="K->E,W: Increases sensitivity to methyl methane
FT                   sulfonate, camptothecin and hydroxyurea (genotoxic
FT                   stress)."
FT                   /evidence="ECO:0000269|PubMed:18719104"
FT   MUTAGEN         290
FT                   /note="K->R: Normal histone acetylase activity. Increases
FT                   sensitivity to methyl methane sulfonate, camptothecin and
FT                   hydroxyurea (genotoxic stress)."
FT                   /evidence="ECO:0000269|PubMed:18568037,
FT                   ECO:0000269|PubMed:18719104"
FT   MUTAGEN         292
FT                   /note="R->E: Decreases activity stimulation by ASF1."
FT                   /evidence="ECO:0000269|PubMed:21256037"
FT   MUTAGEN         312
FT                   /note="W->A: Increases sensitivity to methyl methane
FT                   sulfonate, camptothecin and hydroxyurea (genotoxic
FT                   stress)."
FT                   /evidence="ECO:0000269|PubMed:18719104"
FT   MUTAGEN         355..356
FT                   /note="RK->EE: Decreases binding and activity stimulation
FT                   by VPS75."
FT                   /evidence="ECO:0000269|PubMed:21256037"
FT   MUTAGEN         368..371
FT                   /note="EEYD->RRYR: Decreases histone acetylase activity."
FT                   /evidence="ECO:0000269|PubMed:21256037"
FT   MUTAGEN         368
FT                   /note="E->R: Decreases histone acetylase activity."
FT                   /evidence="ECO:0000269|PubMed:21256037"
FT   MUTAGEN         374
FT                   /note="E->R: Decreases activity stimulation by VPS75."
FT                   /evidence="ECO:0000269|PubMed:21256037"
FT   MUTAGEN         378..382
FT                   /note="EAFTN->RAFTR: Decreases binding and activity
FT                   stimulation by VPS75. Decreases acetylation of histone H3
FT                   'Lys-9' and 'Lys-27'."
FT                   /evidence="ECO:0000269|PubMed:21256037"
FT   MUTAGEN         378
FT                   /note="E->R: Decreases activity stimulation by VPS75."
FT                   /evidence="ECO:0000269|PubMed:21256037"
FT   MUTAGEN         425..436
FT                   /note="Missing: Abolishes ASF1 binding."
FT                   /evidence="ECO:0000269|PubMed:31387991"
FT   HELIX           3..10
FT                   /evidence="ECO:0007829|PDB:2ZFN"
FT   STRAND          16..23
FT                   /evidence="ECO:0007829|PDB:2ZFN"
FT   STRAND          27..29
FT                   /evidence="ECO:0007829|PDB:2ZFN"
FT   STRAND          37..40
FT                   /evidence="ECO:0007829|PDB:3Q68"
FT   STRAND          44..57
FT                   /evidence="ECO:0007829|PDB:2ZFN"
FT   STRAND          60..77
FT                   /evidence="ECO:0007829|PDB:2ZFN"
FT   STRAND          79..90
FT                   /evidence="ECO:0007829|PDB:2ZFN"
FT   HELIX           100..112
FT                   /evidence="ECO:0007829|PDB:2ZFN"
FT   HELIX           117..120
FT                   /evidence="ECO:0007829|PDB:2ZFN"
FT   STRAND          121..124
FT                   /evidence="ECO:0007829|PDB:2ZFN"
FT   HELIX           135..137
FT                   /evidence="ECO:0007829|PDB:2ZFN"
FT   HELIX           144..158
FT                   /evidence="ECO:0007829|PDB:3Q66"
FT   STRAND          159..161
FT                   /evidence="ECO:0007829|PDB:3Q66"
FT   HELIX           164..167
FT                   /evidence="ECO:0007829|PDB:3Q66"
FT   HELIX           169..174
FT                   /evidence="ECO:0007829|PDB:3Q66"
FT   STRAND          175..177
FT                   /evidence="ECO:0007829|PDB:3Q66"
FT   HELIX           182..184
FT                   /evidence="ECO:0007829|PDB:3QM0"
FT   STRAND          186..193
FT                   /evidence="ECO:0007829|PDB:2ZFN"
FT   HELIX           195..197
FT                   /evidence="ECO:0007829|PDB:3Q66"
FT   STRAND          199..201
FT                   /evidence="ECO:0007829|PDB:2ZFN"
FT   HELIX           204..206
FT                   /evidence="ECO:0007829|PDB:2ZFN"
FT   STRAND          207..209
FT                   /evidence="ECO:0007829|PDB:3QM0"
FT   HELIX           215..233
FT                   /evidence="ECO:0007829|PDB:2ZFN"
FT   STRAND          239..243
FT                   /evidence="ECO:0007829|PDB:2ZFN"
FT   HELIX           249..256
FT                   /evidence="ECO:0007829|PDB:2ZFN"
FT   STRAND          259..262
FT                   /evidence="ECO:0007829|PDB:3Q68"
FT   STRAND          264..267
FT                   /evidence="ECO:0007829|PDB:2ZFN"
FT   HELIX           273..276
FT                   /evidence="ECO:0007829|PDB:3CZ7"
FT   HELIX           278..280
FT                   /evidence="ECO:0007829|PDB:2ZFN"
FT   HELIX           292..299
FT                   /evidence="ECO:0007829|PDB:2ZFN"
FT   TURN            303..305
FT                   /evidence="ECO:0007829|PDB:2ZFN"
FT   HELIX           308..318
FT                   /evidence="ECO:0007829|PDB:2ZFN"
FT   HELIX           320..323
FT                   /evidence="ECO:0007829|PDB:2ZFN"
FT   TURN            324..326
FT                   /evidence="ECO:0007829|PDB:3Q66"
FT   STRAND          328..334
FT                   /evidence="ECO:0007829|PDB:2ZFN"
FT   STRAND          336..338
FT                   /evidence="ECO:0007829|PDB:2ZFN"
FT   TURN            346..348
FT                   /evidence="ECO:0007829|PDB:2ZFN"
FT   HELIX           355..366
FT                   /evidence="ECO:0007829|PDB:2ZFN"
FT   HELIX           373..391
FT                   /evidence="ECO:0007829|PDB:2ZFN"
FT   STRAND          396..399
FT                   /evidence="ECO:0007829|PDB:2ZFN"
FT   HELIX           411..423
FT                   /evidence="ECO:0007829|PDB:3Q66"
FT   STRAND          427..429
FT                   /evidence="ECO:0007829|PDB:6F0Y"
SQ   SEQUENCE   436 AA;  50096 MW;  17825D6EF97C4BB5 CRC64;
     MSLNDFLSSV LPVSEQFEYL SLQSIPLETH AVVTPNKDDK RVPKSTIKTQ HFFSLFHQGK
     VFFSLEVYVY VTLWDEADAE RLIFVSKADT NGYCNTRVSV RDITKIILEF ILSIDPNYYL
     QKVKPAIRSY KKISPELISA ASTPARTLRI LARRLKQSGS TVLKEIESPR FQQDLYLSFT
     CPREILTKIC LFTRPASQYL FPDSSKNSKK HILNGEELMK WWGFILDRLL IECFQNDTQA
     KLRIPGEDPA RVRSYLRGMK YPLWQVGDIF TSKENSLAVY NIPLFPDDPK ARFIHQLAEE
     DRLLKVSLSS FWIELQERQE FKLSVTSSVM GISGYSLATP SLFPSSADVI VPKSRKQFRA
     IKKYITGEEY DTEEGAIEAF TNIRDFLLLR MATNLQSLTG KREHRERNQP VPASNINTLA
     ITMLKPRKKA KALPKT
//
